Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Totality of evidence shows aspirin reduces risk of a first heart attack by one-third

18.11.2002


Aspirin conclusively reduces the risk of a first heart attack by 32%, according to a new report by researchers at Mount Sinai Medical Center & Miami Heart Institute. The findings were presented today at the American Heart Association’s Scientific Sessions in Chicago.



Charles H. Hennekens, MD, co-director of Cardiovascular Research, published the first randomized trial of aspirin in primary prevention. Under his direction, Rachel S. Eidelman, MD, a cardiology fellow, performed a detailed meta-analysis of the five randomized trials evaluating aspirin in the primary prevention of a first heart attack. The data conclusively demonstrate that aspirin significantly reduces the risk of a first heart attack by 32% as well as the combined risk of heart attack, stroke and vascular death by 15%.

These findings strongly support the recent guidelines from the American Heart Association (AHA) that aspirin should be recommended for all men and women whose 10-year risks of a first coronary event are 10% or greater. The U.S. Preventive Services Task Force released a similar position earlier this year, urging all physicians to speak about aspirin therapy with patients who have a 6% or greater 10-year risk of a coronary event.


"The individual trials and their meta-analysis strongly support the recent AHA recommendation," noted Dr. Hennekens. "The more widespread and appropriate use of aspirin in primary prevention could avoid more than 160,000 heart attacks and many other vascular events each year."

In 1988, Dr. Hennekens published the landmark Physicians’ Health Study (PHS) findings. The PHS was terminated early due to the emergence of an extreme 44% reduction in risk of a first heart attack among those assigned at random to aspirin. There have been four primary prevention trials published since then, three of which showed similar positive findings for aspirin.

"We found that the current totality of evidence strongly supports our initial findings from the Physicians’ Health Study that aspirin significantly reduces the risk of a first heart attack in apparently healthy individuals," added Dr. Hennekens. "These data, along with the findings that aspirin reduces the risk of death by 23% if given during a heart attack and by 15% in a wide range of people who have survived prior cardiovascular events, demonstrate that more widespread and appropriate use of aspirin in secondary and primary prevention would avoid many premature deaths and heart attacks."

Coronary heart disease is the single leading cause of death in the United States, accounting for more than 500,000 deaths annually. Approximately 80% of deaths from coronary heart disease in people under age 65 occur during the first heart attack.


###
Mount Sinai & Miami Heart’s Cardiovascular Center of Excellence is committed to being a leader in the prevention, diagnosis and treatment of heart disease. The medical center is the largest cardiac services provider in South Florida, conducting approximately 1,300 open heart procedures and approximately 7,400 diagnostic and therapeutic cardiac catheterizations annually. For a physician referral, please call (305) 674-2273.

Lauren Mazzella | EurekAlert!

More articles from Health and Medicine:

nachricht How prenatal maternal infections may affect genetic factors in Autism spectrum disorder
22.03.2017 | University of California - San Diego

nachricht Camouflage apples
22.03.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Pulverizing electronic waste is green, clean -- and cold

22.03.2017 | Materials Sciences

Astronomers hazard a ride in a 'drifting carousel' to understand pulsating stars

22.03.2017 | Physics and Astronomy

New gel-like coating beefs up the performance of lithium-sulfur batteries

22.03.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>